In terms of survival outcomes, Nagai et al. have analyzed nearly 600 samples from patients with breast cancer and found that NDRG1+ tumors were associated with worse outcomes (overall and disease-free survival) than NDRG1− tumors, with 10-year survival rates of 34% for NDRG1+ tumors vs. 67% for NDRG1− tumors [54]. This evidence concerns the gene NDRG1 and breast carcinoma.